Endogenous cannabinoid peptides (hemopressin and related molecules) slowed gastrointestinal motility through CB1 receptors when administered centrally in mice, but with lower potency than classical cannabinoids.
Read this if you follow cannabinoid peptide research or are interested in how new types of cannabinoid drugs might avoid gastrointestinal side effects.
Cannabinoid peptides slowed the gut less potently than classical cannabinoids
What the researchers found
Hemopressin was identified as an endogenous peptide that acts on CB1 cannabinoid receptors. This study tested whether hemopressin and two related peptides (VD-Hpalpha and VD-Hpbeta) affect gastrointestinal motility when delivered directly to the brain.
All three peptides slowed gut movement across multiple measures: upper GI transit, colonic bead expulsion, and whole gut transit. These effects were blocked by the CB1 antagonist AM251 but not by the CB2 antagonist AM630, confirming they work through CB1 receptors.
The key finding for drug development was that these peptides were less potent at slowing the gut than the classical cannabinoid agonist WIN55,212-2. This lower potency on GI function could be therapeutically advantageous: cannabinoid peptides might provide pain relief at doses that do not significantly slow the gut, avoiding a common side effect of cannabinoid drugs.
Why it matters
Cannabinoid-based pain relievers often cause constipation and slowed digestion. If endogenous cannabinoid peptides can provide pain relief at doses below those that significantly affect the gut, they could offer a better therapeutic window than classical cannabinoids.
The numbers in context
All three peptides slowed GI transit via CB1 receptors. Lower potency than WIN55,212-2 on all GI measures. Hpalpha and VD-Hpbeta inhibited whole gut transit at high doses. VD-Hpalpha did not affect whole gut transit. AM251 (CB1 blocker) reversed effects. AM630 (CB2 blocker) did not.
How the study worked
Mouse study using intracerebroventricular (i.c.v.) administration of hemopressin, VD-Hpalpha, VD-Hpbeta, and WIN55,212-2. GI motility measured via upper GI transit (charcoal meal), colonic bead expulsion, and whole gut transit (Evans blue dye). CB1 and CB2 receptor involvement tested with selective antagonists.
What this study cannot tell us
Intracerebroventricular administration does not reflect practical drug delivery. Mouse GI physiology differs from humans. The lower potency could also mean lower analgesic efficacy, which was not tested in this study. Peptide stability and blood-brain barrier penetration pose challenges for drug development.
How to read the evidence
Well-designed mouse study with multiple GI endpoints and selective receptor antagonists, but limited to central administration in rodents.
When this study was published
Published in 2016. Cannabinoid peptide research remains an active area of preclinical investigation.
The bigger picture
The existence of endogenous cannabinoid peptides alongside the well-known lipid endocannabinoids (anandamide and 2-AG) suggests the endocannabinoid system is more complex than previously understood. Peptide cannabinoids could represent a new class of analgesic drugs with improved side effect profiles.
Questions still open
- Can cannabinoid peptides provide pain relief at doses that do not affect GI motility? Would systemically administered peptide analogs show the same favorable separation of effects? Could modified peptides be developed with improved stability and brain penetration?
Common questions
What are endogenous cannabinoid peptides?
Why is lower GI potency a good thing?
Read the original research
Central administrations of hemopressin and related peptides inhibit gastrointestinal motility in mice.
Neurogastroenterology and motility, 28(6), 891-9
Citation
Li, X-H; Lin, M-L; Wang, Z-L; Wang, P; Tang, H-H; Lin, Y-Y; Li, N; Fang, Q; Wang, R. (2016). Central administrations of hemopressin and related peptides inhibit gastrointestinal motility in mice.. Neurogastroenterology and motility, 28(6), 891-9. https://doi.org/10.1111/nmo.12789
Explore the wider topic
- How THC Affects Your Amygdala: The Brain's Threat Detector and Cannabis
- The Anandamide Connection: Your Body's Natural Bliss Molecule
- How Long for Cannabinoid Receptors to Return to Normal
- Cannabis and the Developing Brain: What Every Teenager (and Parent) Should Know
- Why Can't I Enjoy Anything Without Weed? The Science Behind It
- Dopamine Recovery After Quitting Weed: What the Science Says
- The Endocannabinoid System Explained Simply: What It Does and Why It Matters
- Your Endocannabinoid System Explained: Why Withdrawal Happens
- Your Nervous System After Quitting Weed: Fight or Flight
- Using Weed Under 18: What It Does to Your Developing Brain
- What THC Does to Your Brain: Why Withdrawal Happens
- THC and Your Prefrontal Cortex: What Cannabis Does to Your Decision-Making Brain
- Weed, Cortisol, and Stress: What Cannabis Does to Your Stress Hormones
- Weed and Memory: What the Science Says About THC and Your Hippocampus
- Weed and Motivation: Is Amotivational Syndrome Real?
- Weed and Your Nervous System: What THC Actually Does to Your Brain and Body
- How Weed Rewires Your Reward System (And How to Reset It)